Nexentis Technologies Inc. Common Stock (NXTS) Stock Price

NXTSStock

$0.65−97.71%52W

Market Cap$937,545.118

P/E—

PEG Ratio—

Div yield—

Beta1.97

NXTS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-94.58%

Price vs S&P 500 (4W)-51.93%

VGM Score22.90

Book Value / Share (Quarterly)$1.31

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-21.85%

Cash Flow / Share (Quarterly)$-3.11

Price vs S&P 500 (YTD)-106.44%

Gross Margin (TTM)66.20%

Net Profit Margin (TTM)-1024.74%

EPS (TTM)$-55.49

10-Day Avg Trading Volume1.97M

EPS Excl Extra (TTM)$-55.49

Revenue Growth (5Y)3.13%

EPS (Annual)$-217.64

ROI (Annual)-109.35%

Gross Margin (Annual)21.43%

Net Profit Margin (5Y Avg)-1641.43%

Cash / Share (Quarterly)$6.11

Revenue Growth QoQ (YoY)-78.02%

ROA (Last FY)-95.02%

Revenue Growth TTM (YoY)18.94%

EBITD / Share (TTM)$-23.68

ROE (5Y Avg)-109.23%

Operating Margin (TTM)-1414.70%

Cash Flow / Share (Annual)$-9.65

P/B Ratio0.49x

P/B Ratio (Quarterly)3.29x

Net Income / Employee (Annual)$-741,900

EV / Revenue (TTM)-7.17x

Net Interest Coverage (TTM)-2.92x

ROA (TTM)-33.99%

EPS Incl Extra (Annual)$-217.64

Current Ratio (Annual)4.19x

Quick Ratio (Quarterly)3.47x

3-Month Avg Trading Volume1.14M

52-Week Price Return-97.71%

Revenue / Employee (TTM)$29,800

Tangible BV / Share (Quarterly)$11.83

P/S Ratio (Annual)4.46x

Asset Turnover (Annual)0.04x

52-Week High$30.73

Operating Margin (5Y Avg)-1614.45%

EPS Excl Extra (Annual)$-217.64

26-Week Price Return-84.68%

Quick Ratio (Annual)3.52x

13-Week Price Return-71.83%

Total Debt / Equity (Annual)0.06x

Current Ratio (Quarterly)3.72x

Enterprise Value$-6.26M

Revenue / Share Growth (5Y)57.78%

Asset Turnover (TTM)0.03x

Revenue / Employee (Annual)$30,000

Inventory Turnover (Annual)2.32x

Pretax Margin (Annual)-2546.19%

Cash / Share (Annual)$10.28

3-Month Return Std Dev96.41%

Gross Margin (5Y Avg)62.56%

Net Income / Employee (TTM)$-565,000

ROE (Last FY)-109.35%

Net Interest Coverage (Annual)-1.41x

EPS Basic Excl Extra (Annual)$-217.64

Receivables Turnover (TTM)2.67x

Total Debt / Equity (Quarterly)0.22x

EPS Incl Extra (TTM)$-55.49

Receivables Turnover (Annual)1.68x

ROI (TTM)-41.40%

P/S Ratio (TTM)4.50x

Pretax Margin (5Y Avg)-1718.15%

Revenue / Share (Annual)$8.80

Price vs S&P 500 (52W)-113.25%

Year-to-Date Return-94.51%

5-Day Price Return-14.65%

EPS Normalized (Annual)$-217.64

ROA (5Y Avg)-113.47%

Net Profit Margin (Annual)-2472.86%

Month-to-Date Return-53.59%

EBITD / Share (Annual)$-180.55

Operating Margin (Annual)-2057.14%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-102.19%

LT Debt / Equity (Quarterly)0.11x

EPS Basic Excl Extra (TTM)$-55.49

P/TBV (Quarterly)0.39x

P/B Ratio (Annual)0.57x

Inventory Turnover (TTM)2.20x

Pretax Margin (TTM)-1101.95%

Book Value / Share (Annual)$13.79

Price vs S&P 500 (13W)-74.52%

Beta1.97x

Revenue / Share (TTM)$1.51

ROE (TTM)-45.66%

52-Week Low$0.60

gGradeD

mGradeF

vgmGradeD

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NXTSNexentis Technologies Inc. Common Stock	—	D	F	4.5x	18.9%	66.2%	—	$0.65
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.